ESC 2022: Recommendations to prevent heart problems caused by cancer treatment published today

26 August 2022: The first European Society of Cardiology (ESC) guidelines on cardio-oncology were published online today in the European Heart Journal

Guideline download: 2022 ESC Cardio-Oncology Guidelines: Developed in collaboration with European Society of Hematology (EHA), European Society of Radiation Therapy and Oncology (ESTRO) and International Society of Cardio-Oncology (IC-OS): Developed by the Cardiac Disease Working Group - Europe Society of Cardiology (ESC) Oncology

Cancer treatments, including chemotherapy, radiation therapy, targeted therapy, and immunotherapy, have the potential to contribute to cardiovascular disease

Dr Alexander Lyons, of the Royal Brompton Hospital in London, UK, said: "This document is intended for health professionals caring for cancer patients and survivors

The first important issue is to let oncologists and hematologists know which treatments can cause heart problems

The frequency of cardiac monitoring (called surveillance) during treatment that may lead to heart disease, and the option to pre-initiate cardiac medication as a protective option during cancer treatment, can tailor the total amount of cancer treatment to each cancer patient based on baseline risk, nature Duration and dose, and any pre-existing heart disease

Protecting and monitoring heart health during cancer treatment is a key part of this guideline

Recommendations are provided for the diagnosis and management of cardiovascular side effects during cancer treatment

"A variety of factors can influence the decision to continue or stop treatment, including the severity and severity of the heart problem, how early or late the problem is in the cancer management plan and the proposed dose of more treatment, the response to the cancer's response to treatment," Dr.

Some groups recommend monitoring in the first year after treatment

Some patients require long-term monitoring for cardiovascular problems

The guidelines were developed in collaboration with the European Society of Hematology (EHA), the European Society of Radiation Therapy and Oncology (ESTRO) and the International Society of Cardio-Oncology (IC-OS)

Guideline download: 2022 ESC Cardio-Oncology Guidelines: Developed in collaboration with European Society of Hematology (EHA), European Society of Radiation Therapy and Oncology (ESTRO) and International Society of Cardio-Oncology (IC-OS): Developed by the Cardiac Disease Working Group - Europe Society of Cardiology (ESC) Oncology

References:

ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).